@entity1205 and XXXX : an effective regimen in recurrent squamous cell esophageal carcinoma.

@entity1 @entity137 @entity1206 @entity1544 @entity1398 @entity418 @entity3 @entity1282 @entity1205
@entity1206 and @entity1205 are two effective drugs in @entity418 ; our purpose was to evaluate efficacy and @entity137 of a combination of these drugs in recurrent @entity1544 . Twenty @entity1 previously treated with concomitant chemoradiotherapy (n = 14), surgery alone (n = 2), surgery plus radiotherapy (n = 2), or concomitant chemoradiotherapy + surgey (n = 2) were enrolled. Thirteen @entity1 had a local-regional recurrence, two @entity1 had @entity3 , and five @entity1 had both. The doses were 80 mg/m(2) for @entity1205 and 20 mg/m(2) for @entity1206 on d 1 every 21 d for a maximum of six cycles. Twenty @entity1 received a total of 106 cycles (median per @entity1 , 5). @entity1398 was the most frequent and severe side effect (grade 4 in 80%; grade 3 in 20%). The overall response rate was 60%, which included 3 of 20 complete responses (15%) and 9 of 20 partial responses (45%). Median response duration was 7 mo (2-50+). Overall median survival was 10.5 mo (range, 2-55+). A @entity1282 improvement was observed in 81% of @entity1 . In conclusion, the data from this phase II study indicate that this combination is effective in recurrent heavily pretreated @entity1 with a short-lasting manageable @entity137 .
